{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:45:21Z","timestamp":1769064321060,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.mcna.2024.03.010","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:38:29Z","timestamp":1715085509000},"page":"777-794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment and Management of Gastrointestinal Disorders"],"prefix":"10.1016","volume":"108","author":[{"given":"Garren","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsheya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheryl","family":"Pfeil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2024.03.010_bib1","article-title":"Bowel disorders","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.gtc.2020.05.002","article-title":"Refractory constipation: how to evaluate and treat","volume":"49","author":"Camilleri","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5056\/jnm23066","article-title":"2022 seoul consensus on clinical practice guidelines for functional constipation","volume":"29","author":"Cho","year":"2023","journal-title":"J\u00a0Neurogastroenterol Motil"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.010_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cgh.2010.06.031","article-title":"Digital rectal examination is a useful tool for identifying patients with dyssynergia","volume":"8","author":"Tantiphlachiva","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1053\/j.gastro.2012.10.029","article-title":"American Gastroenterological Association medical position statement on constipation","volume":"144","author":"Bharucha","year":"2013","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1016\/j.mcna.2024.03.010_bib6","first-page":"14","article-title":"Two gold kiwifruit daily for effective treatment of constipation in adults-a randomized clinical trial","author":"Bayer","year":"2022","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib7","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.14309\/ajg.0000000000001149","article-title":"Exploratory comparative effectiveness trial of green kiwifruit, psyllium, or prunes in us patients with chronic constipation","volume":"116","author":"Chey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2024.03.010_bib8","article-title":"Systematic review and meta-analysis: Foods, drinks and diets and their effect on chronic constipation in adults","author":"Van Der Schoot","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.010_bib9","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2023.03.214","article-title":"American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: pharmacological management of chronic idiopathic constipation","volume":"164","author":"Chang","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.010_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.12788\/jhm.3124","article-title":"Things we do for no reason: prescribing docusate for constipation in hospitalized adults","volume":"14","author":"Fakheri","year":"2019","journal-title":"J\u00a0Hosp Med"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1543-5946(10)80003-0","article-title":"A\u00a0review of laxative therapies for treatment of chronic constipation in older adults","volume":"8","author":"Fleming","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jpainsymman.2012.02.008","article-title":"Randomized, double-blind, placebo-controlled trial of oral docusate in the management of constipation in hospice patients","volume":"45","author":"Tarumi","year":"2013","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s10620-009-1068-x","article-title":"Efficacy and safety of lubiprostone in patients with chronic constipation","volume":"55","author":"Barish","year":"2010","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.010_bib14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cgh.2014.08.026","article-title":"Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation","volume":"13","author":"Fukudo","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"103","author":"Johanson","year":"2008","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJMoa1010863","article-title":"Two randomized trials of linaclotide for chronic constipation","volume":"365","author":"Lembo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib17","doi-asserted-by":"crossref","first-page":"e13487","DOI":"10.1111\/nmo.13487","article-title":"High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan","volume":"31","author":"Fukudo","year":"2019","journal-title":"Neuro Gastroenterol Motil"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.010_bib18","doi-asserted-by":"crossref","first-page":"e0134349","DOI":"10.1371\/journal.pone.0134349","article-title":"Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: a randomized, controlled trial","volume":"10","author":"Lacy","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ajg.2017.495","article-title":"Efficacy and tolerability of guanylate cyclase-c agonists for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis","volume":"113","author":"Shah","year":"2018","journal-title":"Official journal of the American College of Gastroenterology | ACG"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/gut.2008.162404","article-title":"Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives","volume":"58","author":"Tack","year":"2009","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.mcna.2024.03.010_bib21","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","article-title":"A\u00a0placebo-controlled trial of prucalopride for severe chronic constipation","volume":"358","author":"Camilleri","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","article-title":"Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Quigley","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"10.1016\/j.mcna.2024.03.010_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16183247","article-title":"A\u00a0randomized controlled trial on the effects of electromyographic biofeedback on quality of life and bowel symptoms in elderly women with dyssynergic defecation","volume":"16","author":"Sim\u00f3n","year":"2019","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5152\/tjg.2020.19678","article-title":"Effectiveness of biofeedback therapy on quality of life in patients with dyssynergic defecation disorder","volume":"32","author":"\u00d6zk\u00fct\u00fck","year":"2021","journal-title":"Turk J Gastroenterol"},{"issue":"27","key":"10.1016\/j.mcna.2024.03.010_bib26","first-page":"9162","article-title":"Biofeedback-guided pelvic floor exercise therapy for obstructive defecation: an effective alternative","volume":"20","author":"Ba-Bai-Ke-Re","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2006.05.031","article-title":"Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia","volume":"131","author":"Van Outryve","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/tcmj.tcmj_104_23","article-title":"Update in diagnosis and management of irritable bowel syndrome","volume":"35","author":"Hung","year":"2023","journal-title":"Tzu Chi Med J"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.41.4.505","article-title":"Evidence for two distinct perceptual alterations in irritable bowel syndrome","volume":"41","author":"Naliboff","year":"1997","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/0016-5085(95)90434-4","article-title":"Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome","volume":"108","author":"Accarino","year":"1995","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib31","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2023.08.010","article-title":"Prevalence and burden of illness of rome iv irritable bowel syndrome in the united states: results from a nationwide cross-sectional study","volume":"165","author":"Almario","year":"2023","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.mcna.2024.03.010_bib32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1365-2036.2003.t01-1-01736.x","article-title":"Systematic review: the economic impact of irritable bowel syndrome","volume":"18","author":"Inadomi","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib34","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2014.195","article-title":"The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis","volume":"109","author":"Moayyedi","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41395-018-0195-4","article-title":"A\u00a0systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome","volume":"113","author":"Dionne","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.010_bib36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12906-018-2409-0","article-title":"The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data","volume":"19","author":"Alammar","year":"2019","journal-title":"BMC Complement Altern Med"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.gastro.2022.04.016","article-title":"AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation","volume":"163","author":"Chang","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","article-title":"AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea","volume":"163","author":"Lembo","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2024.03.010_bib40","article-title":"Development and current state of digital therapeutics for irritable bowel syndrome","author":"Brenner","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.15403\/jgld-4090","article-title":"Neuromodulators in the brain-gut axis: their role in the therapy of the irritable bowel syndrome","volume":"30","author":"Fadgyas Stanculete","year":"2021","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib43","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mcna.2024.03.010_bib44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365528709091003","article-title":"Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study","volume":"130","author":"Lav\u00f6","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.mcna.2024.03.010_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/00365528709091004","article-title":"Loperamide treatment of the irritable bowel syndrome","volume":"130","author":"Hovdenak","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.010_bib46","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American gastroenterological association institute technical review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.010_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3389\/fpubh.2020.00293","article-title":"Risk factors for primary clostridium difficile infection; results from the observational study of risk factors for clostridium difficile infection in hospitalized patients with infective diarrhea (ORCHID)","volume":"8","author":"Davies","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib49","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12879-021-06147-y","article-title":"Burden of clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI","volume":"21","author":"Finn","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib50","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1473-3099(18)30285-8","article-title":"Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis","volume":"18","author":"Beinortas","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib51","first-page":"e2778","article-title":"Fidaxomicin vs vancomycin for the treatment of a first episode of clostridium difficile infection: a meta-analysis and systematic review","volume":"10","author":"Al Momani","year":"2018","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib53","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.010_bib54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/M16-0271","article-title":"Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: a randomized trial","volume":"165","author":"Kelly","year":"2016","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib56","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5694\/mja17.00295","article-title":"Faecal microbiota transplantation for <em>Clostridium difficile<\/em>-associated diarrhoea: a systematic review of randomised controlled trials","volume":"207","author":"Moayyedi","year":"2017","journal-title":"Med J Aust"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.010_bib57","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1093\/cid\/ciaa1486","article-title":"Shiga toxin-producing escherichia coli transmission via fecal microbiota transplant","volume":"72","author":"Zellmer","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"21","key":"10.1016\/j.mcna.2024.03.010_bib58","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant e. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.010_bib59","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2013.164","article-title":"Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts","volume":"108","author":"Schwartz","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"Supplement_6","key":"10.1016\/j.mcna.2024.03.010_bib60","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1093\/cid\/ciad642","article-title":"Review article: safety of live biotherapeutic products used for the prevention of clostridioides difficile infection recurrence","volume":"77","author":"Gonzales-Luna","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mcna.2024.03.010_bib61","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1093\/ofid\/ofab466.167","article-title":"167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies","volume":"8","author":"Bancke","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.010_bib63","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1136\/gutjnl-2019-318712","article-title":"Gastroparesis: a turning point in understanding and treatment","volume":"68","author":"Grover","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-018-0038-z","article-title":"Gastroparesis","volume":"4","author":"Camilleri","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib65","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatr"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib66","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2265.2008.03351.x","article-title":"Relationship between clinical features and gastric emptying disturbances in diabetes mellitus","volume":"70","author":"Bharucha","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib67","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cgh.2008.01.009","article-title":"A\u00a0stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research","volume":"6","author":"Szarka","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.mcna.2024.03.010_bib68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11894-020-00761-7","article-title":"Gastroparesis in the 2020s: New Treatments, New Paradigms","volume":"22","author":"Sharma","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib69","article-title":"Su1454 Is gastroparesis a pan-enteric neuropathic disorder: investigation with wireless motility capsule","volume":"148","author":"Siegfried","year":"2015","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.010_bib70","doi-asserted-by":"crossref","first-page":"e13617","DOI":"10.1111\/nmo.13617","article-title":"Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited","volume":"31","author":"Al-Saffar","year":"2019","journal-title":"Neuro Gastroenterol Motil"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.010_bib71","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.14309\/ajg.0000000000000304","article-title":"Prucalopride in gastroparesis: a randomized placebo-controlled crossover study","volume":"114","author":"Carbone","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib72","doi-asserted-by":"crossref","first-page":"650","DOI":"10.5056\/jnm15203","article-title":"Granisetron transdermal system for treatment of symptoms of gastroparesis: a prescription registry study","volume":"22","author":"Midani","year":"2016","journal-title":"J\u00a0Neurogastroenterol Motil"},{"issue":"1","key":"10.1016\/j.mcna.2024.03.010_bib73","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2017.08.033","article-title":"Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders","volume":"154","author":"Pasricha","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mcna.2024.03.010_bib74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.autneu.2016.03.004","article-title":"Systematic review and meta-analysis: Gastric electrical stimulation for gastroparesis","volume":"202","author":"Levinthal","year":"2017","journal-title":"Auton Neurosci"},{"issue":"9","key":"10.1016\/j.mcna.2024.03.010_bib75","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1365-2036.2007.03467.x","article-title":"Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis","volume":"26","author":"Arts","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mcna.2024.03.010_bib76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1572-0241.2007.01676.x","article-title":"Botulinum toxin A for the treatment of delayed gastric emptying","volume":"103","author":"Friedenberg","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.010_bib77","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1111\/nmo.12854","article-title":"Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes","volume":"28","author":"Mekaroonkamol","year":"2016","journal-title":"Neuro Gastroenterol Motil"},{"key":"10.1016\/j.mcna.2024.03.010_bib78","article-title":"Can we use old NAFLD data under the new MASLD definition?","author":"Song","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.mcna.2024.03.010_bib79","article-title":"Fibrosis AGftSoL. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","author":"Ratziu","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib80","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib81","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.clnu.2018.11.030","article-title":"A\u00a0systematic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease","volume":"38","author":"Chen","year":"2019","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib82","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib83","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.mcna.2024.03.010_bib84","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.010_bib85","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMc1006581","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"363","author":"Violi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10019","key":"10.1016\/j.mcna.2024.03.010_bib86","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.010_bib87","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A\u00a0placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.mcna.2024.03.010_bib88","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or t2dm and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib89","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1053\/j.gastro.2019.01.026","article-title":"Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis","volume":"156","author":"Kaplan","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib90","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A\u00a0phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2024.03.010_bib91","doi-asserted-by":"crossref","first-page":"n72","DOI":"10.1136\/bmj.n72","article-title":"Management of colonic diverticulitis","volume":"372","author":"Peery","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mcna.2024.03.010_bib92","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1053\/j.gastro.2020.09.059","article-title":"AGA clinical practice update on medical management of colonic diverticulitis: expert review","volume":"160","author":"Peery","year":"2021","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.mcna.2024.03.010_bib93","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/ajg.2015.302","article-title":"Temporal trends in the incidence and natural history of diverticulitis: a population-based study","volume":"110","author":"Bharucha","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.mcna.2024.03.010_bib94","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/DCR.0000000000001330","article-title":"Treatment of uncomplicated acute diverticulitis without antibiotics: a systematic review and meta-analysis","volume":"62","author":"Au","year":"2019","journal-title":"Dis Colon Rectum"},{"issue":"6","key":"10.1016\/j.mcna.2024.03.010_bib95","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/DCR.0000000000001679","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of left-sided colonic diverticulitis","volume":"63","author":"Hall","year":"2020","journal-title":"Dis Colon Rectum"},{"issue":"17","key":"10.1016\/j.mcna.2024.03.010_bib96","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMcp1800468","article-title":"Diverticulitis","volume":"379","author":"Young-Fadok","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571252400035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002571252400035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T06:11:49Z","timestamp":1722319909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002571252400035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S002571252400035X"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.010","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and Management of Gastrointestinal Disorders","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2024.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}